Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 12 | 2019 | 765 | 1.060 |
Why?
|
Brain Neoplasms | 10 | 2020 | 638 | 0.980 |
Why?
|
Endothelium, Vascular | 8 | 2018 | 156 | 0.970 |
Why?
|
Angiopoietin-1 | 4 | 2012 | 5 | 0.590 |
Why?
|
Myocytes, Smooth Muscle | 2 | 2015 | 72 | 0.540 |
Why?
|
Gap Junctions | 1 | 2015 | 2 | 0.510 |
Why?
|
Connexin 43 | 1 | 2015 | 4 | 0.510 |
Why?
|
Neovascularization, Pathologic | 5 | 2016 | 82 | 0.480 |
Why?
|
Endothelial Cells | 1 | 2015 | 189 | 0.460 |
Why?
|
Brain Injuries | 3 | 2018 | 93 | 0.390 |
Why?
|
Cell Line, Tumor | 9 | 2020 | 726 | 0.360 |
Why?
|
Animals | 20 | 2020 | 7542 | 0.360 |
Why?
|
Receptor, TIE-2 | 3 | 2005 | 5 | 0.330 |
Why?
|
Cell Proliferation | 8 | 2020 | 604 | 0.320 |
Why?
|
Mice | 11 | 2020 | 2484 | 0.320 |
Why?
|
Neovascularization, Physiologic | 2 | 2006 | 110 | 0.310 |
Why?
|
Radiosurgery | 3 | 2017 | 356 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 0.290 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2006 | 210 | 0.290 |
Why?
|
Radiation Injuries | 3 | 2017 | 76 | 0.280 |
Why?
|
Gene Expression | 2 | 2018 | 338 | 0.270 |
Why?
|
Angiopoietins | 1 | 2005 | 2 | 0.250 |
Why?
|
Mesoderm | 1 | 2004 | 14 | 0.250 |
Why?
|
Mesothelioma | 2 | 2001 | 39 | 0.230 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2012 | 112 | 0.220 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2018 | 63 | 0.200 |
Why?
|
Neoplastic Stem Cells | 2 | 2019 | 99 | 0.200 |
Why?
|
Humans | 23 | 2020 | 32114 | 0.200 |
Why?
|
Receptor, erbB-2 | 3 | 2019 | 65 | 0.190 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2001 | 14 | 0.190 |
Why?
|
Mice, Nude | 6 | 2020 | 291 | 0.190 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2001 | 57 | 0.190 |
Why?
|
Sulfones | 1 | 2020 | 21 | 0.180 |
Why?
|
Microglia | 2 | 2018 | 57 | 0.180 |
Why?
|
Indans | 1 | 2020 | 31 | 0.180 |
Why?
|
Fibronectins | 2 | 2018 | 36 | 0.180 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 46 | 0.180 |
Why?
|
Angiotensin I | 2 | 2013 | 241 | 0.180 |
Why?
|
Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.160 |
Why?
|
Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
Peptide Fragments | 2 | 2013 | 399 | 0.160 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 45 | 0.160 |
Why?
|
Glioblastoma | 1 | 2020 | 156 | 0.160 |
Why?
|
Microfilament Proteins | 1 | 2018 | 31 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2019 | 414 | 0.160 |
Why?
|
Radiation Injuries, Experimental | 1 | 2018 | 36 | 0.160 |
Why?
|
Transcription Factors | 1 | 2019 | 181 | 0.160 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 101 | 0.150 |
Why?
|
Astrocytes | 2 | 2019 | 58 | 0.150 |
Why?
|
MAP Kinase Signaling System | 2 | 2019 | 61 | 0.150 |
Why?
|
Cerebrovascular Circulation | 1 | 2018 | 93 | 0.150 |
Why?
|
Exosomes | 1 | 2018 | 43 | 0.150 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 608 | 0.150 |
Why?
|
Signal Transduction | 3 | 2016 | 682 | 0.150 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 181 | 0.140 |
Why?
|
Calcium | 1 | 2019 | 307 | 0.140 |
Why?
|
RNA, Messenger | 3 | 2015 | 508 | 0.140 |
Why?
|
Bone Neoplasms | 1 | 2018 | 111 | 0.140 |
Why?
|
Meningeal Neoplasms | 1 | 2017 | 49 | 0.140 |
Why?
|
Brain | 4 | 2018 | 951 | 0.140 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 52 | 0.140 |
Why?
|
Cranial Irradiation | 1 | 2017 | 93 | 0.140 |
Why?
|
Extracellular Matrix | 1 | 2018 | 245 | 0.140 |
Why?
|
Neoplasms | 1 | 2003 | 728 | 0.130 |
Why?
|
MicroRNAs | 1 | 2018 | 180 | 0.130 |
Why?
|
Epilepsy | 1 | 2017 | 82 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2019 | 261 | 0.130 |
Why?
|
Hippocampus | 2 | 2014 | 171 | 0.130 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 190 | 0.130 |
Why?
|
Culture Media, Conditioned | 1 | 2015 | 51 | 0.130 |
Why?
|
Cell Communication | 1 | 2015 | 32 | 0.130 |
Why?
|
Female | 13 | 2019 | 20015 | 0.120 |
Why?
|
Cesium Radioisotopes | 1 | 2014 | 5 | 0.120 |
Why?
|
Cosmic Radiation | 1 | 2014 | 14 | 0.120 |
Why?
|
Models, Biological | 3 | 2019 | 392 | 0.110 |
Why?
|
Radiation-Protective Agents | 1 | 2013 | 5 | 0.110 |
Why?
|
Oxygen | 1 | 2014 | 142 | 0.110 |
Why?
|
PPAR alpha | 1 | 2014 | 29 | 0.110 |
Why?
|
Rats | 5 | 2014 | 1596 | 0.110 |
Why?
|
Carrier Proteins | 1 | 2013 | 136 | 0.110 |
Why?
|
Cognition | 2 | 2014 | 556 | 0.110 |
Why?
|
Carcinoma, Basal Cell | 1 | 2012 | 26 | 0.100 |
Why?
|
Angiopoietin-2 | 1 | 2012 | 3 | 0.100 |
Why?
|
Immunohistochemistry | 3 | 2019 | 538 | 0.100 |
Why?
|
Cell Movement | 2 | 2020 | 169 | 0.100 |
Why?
|
Down-Regulation | 3 | 2018 | 142 | 0.100 |
Why?
|
Up-Regulation | 2 | 2018 | 189 | 0.100 |
Why?
|
Phosphorylation | 3 | 2010 | 229 | 0.100 |
Why?
|
Cognition Disorders | 1 | 2014 | 385 | 0.090 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 495 | 0.090 |
Why?
|
Lung Diseases, Interstitial | 1 | 2010 | 8 | 0.090 |
Why?
|
Blotting, Western | 3 | 2010 | 289 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2010 | 30 | 0.090 |
Why?
|
Survival Rate | 3 | 2019 | 877 | 0.090 |
Why?
|
Male | 9 | 2019 | 19217 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 166 | 0.080 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2006 | 2 | 0.080 |
Why?
|
Time Factors | 4 | 2013 | 2151 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 352 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2019 | 2265 | 0.070 |
Why?
|
Inflammation | 3 | 2016 | 530 | 0.070 |
Why?
|
Macaca mulatta | 2 | 2018 | 305 | 0.070 |
Why?
|
Malvaceae | 1 | 2005 | 1 | 0.060 |
Why?
|
Proanthocyanidins | 1 | 2005 | 1 | 0.060 |
Why?
|
Biflavonoids | 1 | 2005 | 1 | 0.060 |
Why?
|
Catechin | 1 | 2005 | 5 | 0.060 |
Why?
|
Placentation | 1 | 2005 | 4 | 0.060 |
Why?
|
Embryonic Development | 1 | 2005 | 7 | 0.060 |
Why?
|
Arteriovenous Malformations | 1 | 2005 | 8 | 0.060 |
Why?
|
Hypertension, Pulmonary | 1 | 2005 | 24 | 0.060 |
Why?
|
Hematopoiesis | 1 | 2005 | 33 | 0.060 |
Why?
|
Nonmuscle Myosin Type IIB | 1 | 2004 | 1 | 0.060 |
Why?
|
Laminin | 1 | 2004 | 16 | 0.060 |
Why?
|
Immunoprecipitation | 1 | 2004 | 33 | 0.060 |
Why?
|
Actins | 1 | 2004 | 51 | 0.060 |
Why?
|
Chemotaxis | 1 | 2004 | 24 | 0.060 |
Why?
|
Proteoglycans | 1 | 2004 | 32 | 0.060 |
Why?
|
Extracellular Matrix Proteins | 1 | 2004 | 45 | 0.060 |
Why?
|
Arthritis | 1 | 2005 | 40 | 0.060 |
Why?
|
Plant Extracts | 1 | 2005 | 61 | 0.060 |
Why?
|
Muscle, Smooth | 1 | 2004 | 68 | 0.060 |
Why?
|
Drug Combinations | 1 | 2004 | 98 | 0.060 |
Why?
|
Diabetic Retinopathy | 1 | 2005 | 65 | 0.060 |
Why?
|
Prognosis | 2 | 2019 | 1497 | 0.060 |
Why?
|
Rats, Inbred F344 | 2 | 2014 | 133 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 263 | 0.060 |
Why?
|
Myosin Heavy Chains | 1 | 2004 | 89 | 0.060 |
Why?
|
Middle Aged | 5 | 2019 | 11839 | 0.060 |
Why?
|
Wound Healing | 1 | 2005 | 185 | 0.060 |
Why?
|
Salvage Therapy | 2 | 2016 | 134 | 0.060 |
Why?
|
Collagen | 1 | 2004 | 225 | 0.060 |
Why?
|
Apoptosis | 2 | 2002 | 360 | 0.050 |
Why?
|
Dual Specificity Phosphatase 1 | 2 | 2013 | 29 | 0.050 |
Why?
|
CDC2-CDC28 Kinases | 1 | 2001 | 1 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2004 | 767 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2002 | 101 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2001 | 3 | 0.050 |
Why?
|
Pregnancy | 1 | 2005 | 997 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2001 | 7 | 0.050 |
Why?
|
Paracrine Communication | 1 | 2001 | 9 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2001 | 85 | 0.050 |
Why?
|
Aged | 4 | 2019 | 10314 | 0.050 |
Why?
|
Tumor Cells, Cultured | 3 | 2010 | 171 | 0.050 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 31 | 0.050 |
Why?
|
Nitric Oxide Synthase | 1 | 2000 | 35 | 0.050 |
Why?
|
Isoenzymes | 1 | 2000 | 61 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.040 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 72 | 0.040 |
Why?
|
HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
Electromagnetic Fields | 1 | 2019 | 26 | 0.040 |
Why?
|
Receptors, Estrogen | 2 | 2012 | 113 | 0.040 |
Why?
|
Radiotherapy, Conformal | 1 | 2018 | 19 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 62 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 322 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.040 |
Why?
|
Cell Division | 3 | 2002 | 99 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 101 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2013 | 834 | 0.030 |
Why?
|
Stilbenes | 1 | 2016 | 23 | 0.030 |
Why?
|
Nerve Tissue Proteins | 1 | 2017 | 120 | 0.030 |
Why?
|
Neuronal Plasticity | 1 | 2017 | 80 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2016 | 108 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2019 | 308 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2019 | 1022 | 0.030 |
Why?
|
Adult | 3 | 2018 | 9380 | 0.030 |
Why?
|
Rats, Inbred BN | 1 | 2014 | 31 | 0.030 |
Why?
|
Respiration | 1 | 2014 | 27 | 0.030 |
Why?
|
Dentate Gyrus | 1 | 2014 | 6 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 26 | 0.030 |
Why?
|
Neurogenesis | 1 | 2014 | 16 | 0.030 |
Why?
|
Space Flight | 1 | 2014 | 22 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2014 | 81 | 0.030 |
Why?
|
Gamma Rays | 1 | 2014 | 25 | 0.030 |
Why?
|
Ramipril | 1 | 2013 | 4 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2013 | 31 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 301 | 0.030 |
Why?
|
Receptors, Metabotropic Glutamate | 1 | 2013 | 24 | 0.030 |
Why?
|
Tetrazoles | 1 | 2013 | 61 | 0.030 |
Why?
|
Imidazoles | 1 | 2013 | 91 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2013 | 62 | 0.030 |
Why?
|
Visual Acuity | 1 | 2014 | 73 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 510 | 0.030 |
Why?
|
Prospective Studies | 1 | 2019 | 2283 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 72 | 0.030 |
Why?
|
Treatment Failure | 1 | 2012 | 162 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2014 | 250 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2012 | 81 | 0.030 |
Why?
|
Body Weight | 1 | 2014 | 310 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 153 | 0.020 |
Why?
|
Motor Activity | 1 | 2014 | 325 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2012 | 447 | 0.020 |
Why?
|
Cell Line | 1 | 2012 | 435 | 0.020 |
Why?
|
Neurons | 1 | 2014 | 410 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2019 | 3510 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 43 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 52 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2018 | 3990 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 91 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2010 | 64 | 0.020 |
Why?
|
Fibrosis | 1 | 2010 | 120 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2017 | 3306 | 0.020 |
Why?
|
Benzo(a)pyrene | 1 | 2005 | 2 | 0.020 |
Why?
|
Serine | 1 | 2005 | 10 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2005 | 10 | 0.020 |
Why?
|
Immunoblotting | 1 | 2005 | 51 | 0.020 |
Why?
|
Young Adult | 1 | 2012 | 2665 | 0.020 |
Why?
|
Membrane Potentials | 1 | 2005 | 81 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2005 | 82 | 0.020 |
Why?
|
Breast | 1 | 2005 | 68 | 0.020 |
Why?
|
Antioxidants | 1 | 2005 | 115 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2005 | 141 | 0.010 |
Why?
|
Mitochondria | 1 | 2005 | 187 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2001 | 2 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2001 | 2 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2001 | 4 | 0.010 |
Why?
|
Thymidine | 1 | 2001 | 6 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2002 | 18 | 0.010 |
Why?
|
G1 Phase | 1 | 2001 | 11 | 0.010 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2001 | 9 | 0.010 |
Why?
|
Caspase 3 | 1 | 2001 | 33 | 0.010 |
Why?
|
Caspases | 1 | 2001 | 39 | 0.010 |
Why?
|
Cell Count | 1 | 2001 | 47 | 0.010 |
Why?
|
Species Specificity | 1 | 2001 | 90 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2002 | 122 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 37 | 0.010 |
Why?
|
Cattle | 1 | 2001 | 103 | 0.010 |
Why?
|
Organ Specificity | 1 | 2001 | 81 | 0.010 |
Why?
|
Protein-Serine-Threonine Kinases | 1 | 2001 | 50 | 0.010 |
Why?
|
Vasodilation | 1 | 2002 | 94 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 359 | 0.010 |
Why?
|
Amidines | 1 | 2000 | 2 | 0.010 |
Why?
|
Benzylamines | 1 | 2000 | 5 | 0.010 |
Why?
|
Nitrobenzenes | 1 | 2000 | 10 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2000 | 14 | 0.010 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2000 | 15 | 0.010 |
Why?
|
Asbestos | 1 | 2000 | 8 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2000 | 48 | 0.010 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2000 | 40 | 0.010 |
Why?
|
Sulfonamides | 1 | 2000 | 67 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2000 | 166 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2000 | 256 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 633 | 0.010 |
Why?
|
Lung | 1 | 2000 | 249 | 0.010 |
Why?
|